Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Rosetta Genomics, Precipio commercial partnership, 4/15

April 2015—Rosetta Genomics has entered into a co-promotional commercial partnership with Precipio Diagnostics for the sales and marketing of Precipio’s oncology tests, which include bone marrow and peripheral blood testing for hematological malignancies, such as leukemias and lymphomas. These products are being promoted by Rosetta in California, Connecticut, New Jersey, Oklahoma, Texas, Virginia, and Washington, DC, with an expectation to expand nationally over time.

FDA clearance for breast cancer analysis platform, 4/15

April 2015—Applied Spectral Imaging has received FDA clearance for its GenASIs HiPath image capture and analysis platform. The ASI platform for immunohistochemistry samples integrates with existing lab microscopes and workflows, aiming to provide labs with a cost-effective solution for digital pathology.

Image analysis software, 4/15

April 2015—Definiens announced the newest version of its image analysis software for quantitative digital pathology, Tissue Studio 4.0. By providing morphological fingerprints and biomarker expression profiles on a cell-by-cell basis, the software enables comprehensive and consistent data for any tissue-based assay. It is also able to handle biological variation and staining heterogeneity.

RNA fusion lung cancer research panel, 4/15

April 2015—Thermo Fisher Scientific has released a next-generation sequencing RNA panel and workflow that enables targeted sequencing of fusion transcripts for clinical research. The Ion Torrent AmpliSeq RNA Fusion Lung Cancer Research Panel allows simultaneous sequencing of 70 ALK, RET, ROS1, and NTRK1 fusion transcripts associated with lung cancer as well as 5’ and 3’ ALK gene expression.

Nuclea Biotechnologies partners with BacterioScan, 4/15

April 2015—Nuclea Biotechnologies is partnering with St. Louis-based BacterioScan to validate the BacterioScan 216Dx instrument in a CLIA-certified laboratory. This collaboration will focus on antimicrobial susceptibility testing to guide the best course of antibiotic treatment for different strains of urinary tract infections.

EGFR liquid biopsy test receives CE-IVD mark, 4/15

April 2015—Qiagen announced the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess a genomic mutation in patients with non-small cell lung cancer.

Four new systems from Illumina, 4/15

April 2015—Illumina has launched the HiSeq X Five System and HiSeq 3000/4000 systems and has introduced the NextSeq 550 System, an NGS system enabled for array scanning. The HiSeq X Five System is designed for laboratories wanting to take advantage of HiSeq X technology for human whole genome sequencing at a smaller scale. At full utilization, the system, which consists of five individual HiSeq X instruments, provides the throughput to sequence more than 9,000 genomes a year.

Advanced cervical imaging system, 4/15

April 2015—The Dysis Advanced Cervical Imaging System, a computerized diagnostic tool designed to assist in the early detection of cancerous and precancerous cervical lesions, is available from Dysis Medical in the U.S. after undergoing testing and review in Europe.

Biocartis to develop rapid Ebola virus triage test, 4/15

April 2015—Biocartis announced it is in the testing phase of a Rapid Ebola Virus Triage Test that it is developing in association with Janssen Diagnostics and the Institute for Tropical Medicine in Antwerp, Belgium, for its Idylla system, a CE-IVD-marked, fully automated molecular diagnostic platform.

Antimicrobial susceptibility testing standards, 4/15

April 2015—The Clinical and Laboratory Standards Institute released a new edition of its annual supplement “Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement (M100-S25).” This document provides the revised breakpoints, new testing recommendations, and reporting changes needed to incorporate into routine practice for improving detection and reporting of antimicrobial resistance.

MARKETPLACE

TRENDING